Advertisement

Methamphetamine psychosis: Lack of association with stimulant prescription ADHD medications

Published:March 11, 2019DOI:https://doi.org/10.1016/j.ajem.2019.03.018
      Methamphetamine use is increasing nationwide [

      Richards JR, Hamidi S, Grant CD, Wang CG, Tabish N, Turnipseed SD, Derlet RW. Methamphetamine use and emergency department utilization: 20 years later. J Addict 2017; 2017: 4050932.

      ]. Recently, cases of methamphetamine psychosis have been increasing in frequency in Montgomery County, Ohio, with up to 40% of methamphetamine users affected [

      Poisoning Death Review Report Montgomery County, 2017. Public Health–Dayton & Montgomery County Prepared by Epidemiology Department Published July 2, 2018.

      ,

      Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs 2014; 28 (12): 1115–26.

      ]. Methamphetamine psychosis is characterized by hallucinations, uncontrolled movements and potential violent behavior, and in a subset of patients may result in recurrent psychotic episodes [

      McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiat 2013 Mar; 70(3): 319–24.

      ]. Poison death review data for Montgomery County shows increasing methamphetamine associated overdose deaths, nearly doubling between 2016 and 2017 [

      Richards JR, Hamidi S, Grant CD, Wang CG, Tabish N, Turnipseed SD, Derlet RW. Methamphetamine use and emergency department utilization: 20 years later. J Addict 2017; 2017: 4050932.

      ].

      Keywords

      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Richards JR, Hamidi S, Grant CD, Wang CG, Tabish N, Turnipseed SD, Derlet RW. Methamphetamine use and emergency department utilization: 20 years later. J Addict 2017; 2017: 4050932.

      2. Poisoning Death Review Report Montgomery County, 2017. Public Health–Dayton & Montgomery County Prepared by Epidemiology Department Published July 2, 2018.

      3. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs 2014; 28 (12): 1115–26.

      4. McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiat 2013 Mar; 70(3): 319–24.

      5. McKetin R1, Lubman DI, Baker AL, Dawe S, Ali RL. American Psychiatric Association: Diagnostic and statistical manual of mental disorders, 5th edition. Arlington, VA., American Psychiatric Association, 2013.

      6. Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, et al. (2018) Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS ONE 13 (11): e0206100. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0206100, Accessed 2/6/2019.

      7. León KS, Martínez DE. To study, to party, or both? Assessing risk factors for non-prescribed stimulant use among middle and high school students. J Psychoactive Drugs 2016; 49(1): 22–30.

      8. Burgard DA, Fuller R, Becker B, Ferrell R, Dinglasan-Panlilio M. Potential trends in attention deficit hyperactivity disorder (ADHD) drug use on a college campus: wastewater analysis of amphetamine and ritalinic acid. Sci Total Environ 2013; 450-451: 242–249.

      9. Fond G, Gavaret M, Llorca P, Boyer L, Micoulaud-Franchi J, Domenech P. (Mis)use of prescribed stimulants in the medical student community: motives and behaviors. A population-based cross-sectional study. Eur Neuropsychopharmacol 2016; 26.